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and Igor D Grachev7,8,9*†Abstract
Introduction: Diagnostic effectiveness of Ioflupane I 123 injection (DaTSCAN™, DaTscan™, or [123I]FP-CIT or
ioflupane [123I]) SPECT imaging, was assessed in patients with clinically uncertain parkinsonian syndrome (CUPS).
Methods: We investigated the association between subject’s Hoehn & Yahr (H&Y) stage, Mini-Mental State Examination
(MMSE), age, and motor symptom subgroups and diagnostic performance of ioflupane [123I] imaging. Phase 4 study
data were used to calculate sensitivity, specificity, positive and negative predictive value, and accuracy in 92 CUPS
subjects, using 1-year clinical diagnosis after ioflupane [123I] imaging as reference standard.
Results: Diagnostic effectiveness of ioflupane [123I] imaging was high in all subgroups: 91% to 100% for H&Y
low (<2) and high (≥2) stage subjects; 93% to 96% for MMSE low (<29) or high (≥29) scores; 91% to100% in
both age subgroups (younger [<68] and older [≥68]); and 92% to 100% in subjects with both tremor dominant
and balanced motor signs. Specificity of ioflupane [123I] imaging for bradykinetic rigid or posturally (BRP)
unstable motor subtype was lower, but better than for baseline clinical diagnosis.
Conclusions: Strongest diagnostic performance of ioflupane [123I] imaging for clinical diagnosis of Parkinson’s
syndrome (PS) or non-PS was associated with tremor and balanced motor dominance rather than with BRP
dominance. High diagnostic effectiveness of ioflupane [123I] imaging and favourable performance relative to final
clinical diagnosis at 1 year post-scan in subjects with CUPS was demonstrated. This study suggests that the diagnostic
performance of ioflupane [123I] imaging in CUPS remains high at all stages of disease, including early stage, and across both
age groups and cognitive state (MMSE).Introduction
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unless otherwise stated.the availability of Ioflupane I 123 injection (DaTSCAN™
or DaTscan™ or [123I]FP-CIT or ioflupane [123I]) imaging
results often led to a significant change in diagnosis
from baseline to 1 year (observed in 55/102 (54%)
subjects who received ioflupane [123I] imaging vs. 26/113
(23%) controls who did not receive ioflupane [123I] im-
aging), an increase in physician’s confidence of the revised
diagnosis, and a significant change in clinical management
[1]. In the current study, we investigated the effect of sub-
ject’s age, disease stage, and other clinical and neurocogni-
tive measures on diagnostic performance of ioflupane
[123I] imaging that have not been reported previously. Wed. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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positive predictive value (PPV), negative predictive value
(NPV), and accuracy) of ioflupane [123I] imaging versus
the final clinical diagnosis for subjects who had both ioflu-
pane [123I] imaging results at baseline and a specific clin-
ical diagnosis 1 year post scan, including analyses based
on subject’s Hoehn and Yahr (H&Y) stage, Mini-Mental
State Examination (MMSE) score, age, and predominant
clinical syndrome subgroup. It has already been estab-
lished that age is a contributing factor in the progressive
decline of dopamine transporter (DaT) binding in healthy
aging subjects [2]. However, it has also been shown that
age of Parkinson’s disease (PD) patients contributes to dis-
ease severity, independent of the duration of disease [3].
Possible effects of age and gender on disease severity
were investigated by Szewczyk-Krolikowski and colleagues,
who observed some clinical/phenotypic heterogeneity in
age and gender subgroups, but the study did not include
ioflupane [123I] imaging [3]. Other investigators have
attempted to use changes in motor symptom scales
(Unified Parkinson’s Disease Rating Scale) as predic-
tors of clinical course, but found no change over time
in a small group of patients with scans without
evidence for dopaminergic deficiency with DaT single-
photon emission computed tomography (SPECT) [4].
Whilst the Unified Parkinson’s Disease Rating Scale ef-
fectively measures the progression of PD symptoms for
the first 10 years of the disease [4], other investigators
have used the H&Y stage, as in the current study, ra-
ther than the Unified Parkinson’s Disease Rating Scale
[5]. Nissen and colleagues found an inverse correlation
of dopamine transporter uptake ratios with H&Y stage
and dosage of antiparkinson drugs [5].
The current analysis was undertaken to evaluate
whether particular patient characteristics – specifically
H&Y stage, MMSE score, age, and clinical syndrome
phenotype – were associated with relatively better or
worse diagnostic performance of ioflupane [123I] im-
aging in CUPS using 1-year post-scan clinical diagnosis
as a reference standard.
Methods
The clinical and imaging methods were reported previ-
ously [1]. Ioflupane [123I] has been validated in several
clinical trials and was approved for use in 2000 in the
EU and in 2011 in the USA [6,7]. Of the 122 subjects
from the phase 4 clinical trial who received ioflupane
[123I] imaging studies, 30 subjects had nonconfirmed
diagnoses at 1 year, disqualifying them from being in-
cluded as a reference standard (confirmed diagnosis at 1
year), resulting in 92 subjects with CUPS who were
qualified for this analysis [1]. The clinical trial was ap-
proved by local ethics committees and their institutional
review boards (see Additional file 1) and was conductedunder the Declaration of Helsinki. Informed consent was
obtained by subjects or their guardians for that trial,
which covered data analysis and publications related to
the study. Ninety-two subjects with complete subgroup-
ing datasets (baseline H&Y stage, baseline MMSE score,
baseline age, predominant motor syndrome, ioflupane
[123I] imaging results. and 1-year clinical diagnosis) were
included in this report. To analyze the effect of the H&Y
stage on diagnostic effectiveness of ioflupane [123I] im-
aging, subjects were classified using a baseline-modified
H&Y stage dichotomized into two groups: stage <2 and
stage ≥2. To analyze the effect of cognitive status of sub-
jects on diagnostic effectiveness of ioflupane [123I] im-
aging, subjects were grouped by scores <29 and ≥29 (for
a detailed explanation of this methodological approach,
see Statistical methods). To analyze the effect of subject’s
age on the diagnostic effectiveness of ioflupane [123I] im-
aging, subjects were classified as <68 or ≥68 years of age
at baseline. Investigators also grouped subjects at base-
line into a predominant clinical motor syndrome sub-
group – tremor dominant; bradykinesia, rigidity, postural
instability (BRP) dominant; or balanced (regarding tremor
and bradykinesia scores) – to determine the effect of
motor symptom subtype on diagnostic effectiveness of
ioflupane [123I] imaging.
Subjects in the tremor dominant subgroup had tremor
scores greater than their maximal score for bradykinesia,
rigidity, or postural instability. Subjects in the BRP dom-
inant subgroup had the maximal score of bradykinesia,
rigidity, or postural instability greater than their score
for tremor. Subjects in the balanced group had maximal
BRP scores equal to tremor scores. The scores were cal-
culated by assigning numbers scores for motor signs: 1
for none, 2 for possible, and 3 for definite.
Data source
Data analyzed included baseline H&Y stage, MMSE score,
age at baseline, predominant clinical syndrome subgroup,
and ioflupane [123I] imaging results in subjects with CUPS
[1]. Subjects with CUPS defined as monosymptomatic,
atypical or incomplete presentation of tremor, rigidity,
bradykinesia or postural instability, and/or had a poor re-
sponse to levodopa were enrolled in the study. Please see
Methods for the selection process of the 92 subjects from
19 hospital centers in Europe (15 centers) and the USA
(four centers) who were included in this report. Subjects
in this study had experienced motor and nonmotor signs
and symptoms, and were under physician observation for
up to a maximum of 5 years prior to ioflupane [123I] im-
aging, which in combination with 1-year post-scan clinical
follow-up provided sufficient rationale for using the 1-year
clinical diagnosis as a reference standard (standard of
truth). The study population receiving ioflupane [123I] im-
aging from which the 92 subjects were selected to be
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2.20 years (median) [1]. Subjects with clinically diagnosed
vascular lesions were not intentionally enrolled, although
enrolling older subjects with some silent vascular changes
would have been unavoidable.
Interpretation of Ioflupane [123I] imaging results
Description of the ioflupane [123I] SPECT imaging meth-
odology has been reported previously [1]. Each recon-
structed ioflupane [123I] SPECT image was categorized as
normal or abnormal by an onsite imaging reader (a nuclear
medicine physician having expertise in neuroimaging) and
interpreted with no access to clinical information, such as
symptoms, clinical signs evolution, treatment, and clinical
management changes.
Statistical methods
The statistical analysis plan was to generate diagnostic
efficacy parameters – sensitivity (equivalent to positive
percent agreement), specificity (equivalent to negative
percent agreement), PPV, NPV, and accuracy – for ioflu-
pane [123I] imaging in subject subgroups. The subgroups
for H&Y stage, MMSE, and subject’s age were based on
dichotomization; that is, an entire population at the me-
dian values (to ensure the same number of subjects in
low and high subgroups). Dichotomization is a common
statistical approach used with limited datasets for which
categorical, more meaningful subdivisions requiring a
much larger sample size cannot be used. The median
values were chosen as the cutoff points to avoid subject-
ivity by the authors and to prevent outliers from having
undue influence. The values we used were H&Y median
score of 2, MMSE median score of 29, and median age
of 68 years, respectively. The subgroups for dominant
motor syndrome were based on a clinically common
classification into tremor dominant, BRP dominant,
and balanced subgroups. Standard methods were employed
to calculate the diagnostic efficacy parameters for ioflupane
[123I] imaging using 1-year post-scan clinical diagnosis asTable 1 Subject subgroup relationship to 1-year clinical diagn
results (n = 92)








<2 ≥2 Total <29 ≥29 To
PS Normal 2 1 3 1 2 3
Abnormal 26 20 46 19 27 46
Non-PS Normal 20 21 41 16 25 41
Abnormal 0 2 2 1 1 2
Total 48 44 92 37 55 92
Data presented as numbers. B, balanced; BRP, bradykinesia, rigidity, postural instabi
MMSE, Mini-Mental State Examination; PS, parkinsonian syndrome; TD, tremor dom
score of BRP = tremor score. Scores for these motor signs were 1 for none, 2 for pothe reference standard (standard of truth). For subjects
with a PS diagnosis at 1 year, an ioflupane [123I] image
reading of abnormal was deemed a true positive, whilst an
ioflupane [123I] reading of normal was deemed a false
negative. For subjects with a non-PS diagnosis at 1 year, an
ioflupane [123I] image reading of normal was deemed a
true negative, whereas an ioflupane [123I] image reading of
abnormal was deemed a false positive. Comparison of
diagnostic efficacy parameters between mutually exclusive
subgroups was performed with Fisher’s exact test.
Results
Study population
The number of subjects analyzed in four subgroups was
92, with approximately equal distribution between normal
and abnormal ioflupane [123I] imaging results among all
subgroups. Table 1 summarizes the various subject sub-
groups in relation to the 1-year clinical diagnosis and
ioflupane [123I] imaging results.
Hoehn and Yahr stage
At baseline, most of the 92 subjects in this group were in
the early stages of disease (H&Y stages 1 to 2), split about
evenly between the two stages. Slightly less than one-half
of the subjects had normal ioflupane [123I] images. The
subjects who had abnormal ioflupane [123I] images were
about evenly split between H&Y stages 1 and 2.
Efficacy parameters for ioflupane [123I] imaging ranged
between 91 and 100% to determine whether or not
subjects had PS or non-PS at 1 year for all diagnostic
efficacy parameters: sensitivity, specificity, accuracy,
PPV, and NPV. In addition, all of the efficacy parameters
showed similar high values for subject groups having
either low (<2) or high (≥2) H&Y stage scores (Table 2,
Figure 1A).
Mini-mental state examination
At baseline, the majority of subjects had MMSE scores <29





tal <68 years ≥68 years Total TD BRP dominant B Total
2 1 3 0 2 1 3
15 31 46 10 17 19 46
15 26 41 25 4 12 41
2 0 2 0 2 0 2
34 58 92 35 25 32 92
lity; CUPS, clinically uncertain parkinsonian syndrome; H&Y, Hoehn and Yahr;
inant. aTD, tremor score > BRP; BRP dominant, BRP > tremor score; B, maximal
ssible, and 3 for definite.
Table 2 Efficacy parameters for prediction of clinical diagnosis 1 year post scan: modified H&Y stage (n = 92)
Subjects with CUPS
Clinical diagnosis at 1 year post-scan
Subgroup: modified H&Y stage <2 Subgroup: modified H&Y stage ≥2
PS Non-PS Total PS Non-PS Total
Abnormal ioflupane [123I] imagesa 26 0 26 20 2 22
Normal ioflupane [123I] images 2 20 22 1 21 22
Total 28 20 48 21 23 44
Statistic Result Exact 95% CI Result Exact 95% CI P value/analysis methodb
Sensitivityc 0.9286 (0.7650, 0.9912) 0.9524 (0.7618, 0.9988) 1.0000
Specificityd 1.0000 (0.8316, 1.0000) 0.9130 (0.7196, 0.9893) 0.4906
Accuracy 0.9583 (0.8575, 0.9949) 0.9318 (0.8134, 0.9857) 0.6673
Positive predictive value 1.0000 (0.8677, 1.0000) 0.9091 (0.7084, 0.9888) 0.2048
Negative predictive value 0.9091 (0.7084, 0.9888) 0.9545 (0.7716, 0.9988) 1.0000
CI, confidence interval; CUPS, clinically uncertain parkinsonian syndrome; H&Y, Hoehn and Yahr; PS: parkinsonian syndrome. aAbnormal imaging types 1, 2 and 3.
bP value is based on Fisher’s exact test. cSensitivity is equivalent to positive percent agreement. dSpecificity is equivalent to negative percent agreement.
Figure 1 Sensitivity and specificity of ioflupane [123I] imaging for prediction of clinical diagnosis, 1 year. (A) Modified Hoehn and Yahr
Stage. (B) Mini-Mental State Examination Score. (C) Age of subjects. (D) Clinical syndrome predominance. NPA, negative percent agreement;
PPA, positive percent agreement.
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Table 3 Efficacy parameters for prediction of clinical diagnosis 1 year post scan: Mini-Mental State Examination
(n = 92)
Subjects with CUPS
Clinical diagnosis at 1 year post-scan
Subgroup: MMSE <29 Subgroup: MMSE ≥29
PS Non-PS Total PS Non-PS Total
Abnormal ioflupane [123I] imagesa 19 1 20 27 1 28
Normal ioflupane [123I] images 1 16 17 2 25 27
Total 20 17 37 29 26 55
Statistic Result Exact 95% CI Result Exact 95% CI P value/analysis
methodb
Sensitivityc 0.9500 (0.7513, 0.9987) 0.9310 (0.7723, 0.9915) 1.0000
Specificityd 0.9412 (0.7131, 0.9985) 0.9615 (0.8036, 0.9990) 1.0000
Accuracy 0.9459 (0.8181, 0.9934) 0.9455 (0.8488, 0.9886) 1.0000
Positive predictive value 0.9500 (0.7513, 0.9987) 0.9643 (0.8165, 0.9991) 1.0000
Negative predictive value 0.9412 (0.7131, 0.9985) 0.9259 (0.7571, 0.9909) 1.0000
CI, confidence interval; CUPS, clinically uncertain parkinsonian syndrome; MMSE, Mini-Mental State Examination; PS, parkinsonian syndrome. aAbnormal imaging
types 1, 2 and 3.
bP value is based on Fisher’s exact test. cSensitivity is equivalent to positive percent agreement. dSpecificity is equivalent to negative percent agreement.
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mately equal for both groups, as were diagnoses of PS and
non-PS at 1 year post scan. Sensitivity, specificity, accuracy,
PPV, and NPV ranged between 94 and 95% for prediction
of clinical diagnosis at 1 year, both in subjects with MMSE
scores <29 and in subjects with MMSE scores ≥29. No no-
ticeable differences were observed between low-scoring
and high-scoring MMSE groups for any of the parameters.
Subject’s age
At baseline, subjects were divided relatively equally
between the younger group (<68 years of age) and the
older group (≥68 years of age) (see Table 4, Figure 1C).
The older group had slightly more subjects with abnor-
mal ioflupane [123I] imaging results than the younger
group. Likewise, diagnoses of PS and non-PS 1 year postTable 4 Efficacy parameters for prediction of clinical diagnos
Subjects with CUPS
Clinical diagnosis at 1 year po
Subgroup: <68 years of age
PS Non-PS
Abnormal ioflupane [123I] imagesa 22 0
Normal ioflupane [123I] images 2 20
Total 24 20
Statistic Result Exact 95% CI
Sensitivityc 0.9167 (0.7300, 0.9897)
Specificityd 1.0000 (0.8316, 1.0000)
Accuracy 0.9545 (0.8453, 0.9944)
Positive predictive value 1.0000 (0.8456, 1.0000)
Negative predictive value 0.9091 (0.7084, 0.9888)
CI, confidence interval; CUPS, clinically uncertain parkinsonian syndrome; PS, parkin
Fisher’s exact test. cSensitivity is equivalent to positive percent agreement. dSpecificdose were evenly divided for both younger and older age
groups. The sensitivity, specificity, accuracy, PPV, and
NPV of ioflupane [123I] imaging were all high (ranged
between 91 and 100%) in both groups. Overall, no
noticeable difference was observed between age groups
for all tested parameters.Clinical syndrome predominance
Subjects with baseline motor signs with predominance of
bradykinesia, rigidity, or postural instability had moderate
(ranged between 67 and 89%) sensitivity, accuracy, and
PPV of ioflupane [123I] imaging (see Table 5, Figure 1D).
The specificity and NPV of ioflupane [123I] imaging were
lower for the BRP dominant subgroup as compared with
other clinical subgroups, both for tremor dominant, foris 1 year post scan: subject’s baseline age (n = 92)
st-scan
Subgroup: ≥68 years of age
Total PS Non-PS Total
22 24 2 26
22 1 21 22
44 25 23 48
Result Exact 95% CI P value/analysis
methodb
0.9600 (0.7965, 0.9990) 0.6092
0.9130 (0.7196, 0.9893) 0.4906
0.9375 (0.8280, 0.9869) 1.0000
0.9231 (0.7487, 0.9905) 0.4929
0.9545 (0.7716, 0.9988) 1.0000
sonian syndrome. aAbnormal imaging types 1, 2 and 3. bP value is based on
ity is equivalent to negative percent agreement.
Table 5 Efficacy parameters for prediction of ioflupane [123I] imaging, 1 year post scan: clinical syndrome
predominance (n = 92)
Subjects with
CUPS
Clinical diagnosis at 1 year post-scan
Subgroup A: BRP dominanta Subgroup B: TDb Subgroup C: balancedc
PS Non-PS Total PS Non-PS Total PS Non-PS Total
Abnormal ioflupane
[123I] imagesd
17 2 19 10 0 10 19 0 19
Normal ioflupane
[123I] images
2 4 6 0 25 25 1 12 13




















































BRP, bradykinesia, rigidity, postural instability; CI, confidence interval; CUPS, clinically uncertain parkinsonian syndrome; NE, not estimable; PS: Parkinsonian
syndrome; TD, tremor dominant. aMaximal score of bradykinesia, rigidity, or postural instability > tremor score. bTremor score > maximal score of bradykinesia,
rigidity, or postural instability. cMaximal score of bradykinesia, rigidity, or postural instability = tremor score. dAbnormal imaging types 1, 2 and 3. eP value is based
on Fisher’s exact test. fSensitivity is equivalent to positive percent agreement. gSpecificity is equivalent to negative percent agreement.
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subgroups (see Methods for definition of subgroups).
In contrast, all of the efficacy parameters of ioflupane
[123I] imaging in subjects with tremor dominant and bal-
anced motor signs ranged between 92 and 100%, showing
specificity of 100% for the tremor dominant and balanced
motor signs subgroups (see Table 5, Figure 1D).
In addition, we estimated the diagnostic effectiveness
of baseline clinical diagnosis without availability of im-
aging results (Table 6) and compared it with the effect-
iveness of ioflupane [123I] imaging (Table 7). Although
the range of observed specificity of baseline clinical diag-
nosis was 33 to 56% for the three subgroups, the differ-
ence in diagnostic performance between these groups
for baseline clinical diagnosis was not significant for all
tested parameters (Table 6).
For the BRP dominant subgroup, the difference between
ioflupane [123I] imaging and baseline clinical diagnosis
was not significant for all tested parameters (Table 7,
Figure 2A).
Comparison of the specificity, PPV, and accuracy of
ioflupane [123I] imaging with the same parameters for
baseline clinical diagnosis (both compared with 1-year
post-scan clinical diagnosis as reference standard) found
significant differences for the tremor dominant and bal-
anced subgroups (Table 7, Figure 2B,C). For the tremor
dominant group, specificity, PPV, and accuracy were
significantly higher for ioflupane [123I] imaging (all100%) as compared with the baseline clinical diagnosis
(ranged between 44 and 66%). For the balanced sub-
group, specificity, PPV, and accuracy were significantly
higher for ioflupane [123I] imaging (100%, 100%, and
97%) as compared with the baseline clinical diagnosis
(54%, 73%, and 74%).
Discussion
Strengths and limitations of the study
The findings in this study are broadly in line with hypo-
thetical predictive models and augment the scant litera-
ture examining the effects of age, clinical stage of PD
and cognitive impairment on the utility of ioflupane
[123I] imaging as an adjunct to clinical diagnosis. This
study is the first robust statistical analysis of several po-
tential influences on the efficacy of ioflupane [123I] im-
aging that measures their effect on image interpretation
and supports the value of imaging in a real-world setting
where clinicians are able to incorporate imaging results
to assist them in making a diagnosis and subsequent
treatment plan. The open-label setting is both a strength
and a possible limitation of the study. Whilst the findings
of the study indicate some utility of ioflupane [123I] in
assisting diagnosis, one of the possible methodological
limitations of this study is that information from the im-
aging scan could have influenced the clinician’s
standard-of-truth diagnosis, causing a shift in the subse-
quent clinical management of the subject [1]. The onsite
Table 7 Comparison: diagnostic performance of ioflupane [123I] imaging with baseline clinical diagnosis (clinical
syndrome predominance, n = 92)
Subjects with CUPS: subgroup Ioflupane [123I] imaging vs. 1-year clinical
diagnosis as reference standard
Baseline clinical diagnosis vs. 1-year
clinical diagnosis as reference standard
P valuea
Result Exact 95% CI Result Exact 95% CI
Subgroup A: BRP dominantb Sensitivityc 0.8947 (0.6686, 0.9870) 1.0000 (0.8389, 1.0000) 0.2192
Specificityd 0.6667 (0.2228, 0.9567) 0.3330 (0.0433, 0.7772) 0.5671
Accuracy 0.8400 (0.6392, 0.9546) 0.8519 (0.6627, 0.9581) 1.0000
PPV 0.8947 (0.6686, 0.9870) 0.8400 (0.6392, 0.9546) 0.6843
NPV 0.6667 (0.2228, 0.9567) 1.0000 (0.1581, 1.0000) 1.0000
Subgroup B: TDe
Sensitivityc 1.0000 (0.6915, 1.0000) 0.8889 (0.5175, 0.9972) 0.4737
Specificityd 1.0000 (0.8628, 1.0000) 0.5652 (0.3449, 0.7681) <0.0001
Accuracy 1.0000 (0.9000, 1.0000) 0.6563 (0.4681, 0.8143) <0.0001
PPV 1.0000 (0.6915, 1.0000) 0.4444 (0.2153, 0.6924) 0.0039
NPV 1.0000 (0.8628, 1.0000) 0.9286 (0.6613, 0.9982) 0.3590
Subgroup C: balancedf
Sensitivityc 0.9500 (0.7513, 0.9987) 0.8500 (0.6211, 0.9679) 0.6050
Specificityd 1.0000 (0.7354, 1.0000) 0.5385 (0.2513, 0.8078) 0.0149
Accuracy 0.9688 (0.8378, 0.9992) 0.7273 (0.5448, 0.8670) 0.0129
PPV 1.0000 (0.8235, 1.0000) 0.7391 (0.5159, 0.8977) 0.0244
NPV 0.9231 0.6397, 0.9981) 0.7000 (0.3475, 0.9333) 0.2806
BRP, bradykinesia, rigidity, postural instability; CI, confidence interval; CUPS, clinically uncertain parkinsonian syndrome; NPV, negative predictive value; PPV,
positive predictive values; TD, tremor dominant. aP value is based on Fisher’s exact test. bMaximal score of bradykinesia, rigidity, or postural instability > tremor
score. cTremor score > maximal score of bradykinesia, rigidity, or postural instability. dMaximal score of bradykinesia, rigidity, or postural instability = tremor score.
eSensitivity is equivalent to positive percent agreement. fSpecificity is equivalent to negative percent agreement.
Table 6 Efficacy: baseline clinical diagnosis, prediction of clinical diagnosis 1 year post scan (clinical syndrome
predominance, n = 92)
Subjects with
CUPS
Clinical diagnosis at 1 year post-scan
Subgroup A: BRP dominanta Subgroup B: TDb Subgroup C: balancedc
Baseline clinical
diagnosis
PS Non-PS Total PS Non-PS Total PS Non-PS Total
Positive (PS) 21 4 25 8 10 18 17 6 23
Negative (non-PS) 0 2 2 1 13 14 3 7 10




















































Scores for motor signs were 1 for none, 2 for possible, and 3 for definite. Excluded were subjects with 1-year clinical diagnosis of inconclusive, subjects with missing
ioflupane [123I] imaging result, or subjects with missing 1-year clinical diagnosis. BRP, bradykinesia, rigidity, postural instability; CI, confidence interval; CUPS, clinically
uncertain parkinsonian syndrome; PS, Parkinsonian syndrome; TD, tremor dominant. aMaximal score of bradykinesia, rigidity, or postural instability > tremor score.
bTremor score > maximal score of bradykinesia, rigidity, or postural instability. c:Maximal score of bradykinesia, rigidity, or postural instability = tremor score.
dP value is based on Fisher’s exact test. eSensitivity is equivalent to positive percent agreement. fSpecificity is equivalent to negative percent agreement.
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Figure 2 Diagnostic performance of ioflupane [123I] imaging versus baseline clinical diagnosis. (A) Sensitivity (PPA, positive percent
agreement). (B) Specificity (NPA, negative percent agreement). (C) Accuracy.
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to the clinical information were based on the findings of
one qualified local reader per study site, and were not the
consensus of a panel of multiple readers, a situation that
was specifically designed to resemble clinical practice. At
the time of the 1-year diagnosis, the general neurologists
or movement disorder specialists had access to imaging
information. The study was designed with a 1-year follow-
up period post scan to be used as a reference standard,
although the efficacy results between 90 and 100% had
already been established in tremor and balanced sub-
groups, showing a potential ceiling effect for the test. It
would be desirable to use a longer follow-up period for
the BRP subgroup as a reference standard. Study subjects
had clinical symptoms up to 5 years prior to enrolment in
the study (mean 2.54 years), which in combination
with the additional 1-year clinical follow-up and avail-
ability of imaging information should generally be
sufficient for the final clinical diagnosis to be used as a
reference standard in tremor and balanced subgroups
[1]. This is the first study showing a difference for
ioflupane [123I] imaging between different motor syn-
drome subgroups, including subjects with CUPS. Be-
cause of the modest study size and possible unequal
distribution of subjects amongst motor syndromes, the
small number of participants in the BRP dominant sub-
group may not be sufficiently powered to adequately ad-
dress real differences in imaging utility from other motor
subgroups. Despite this, the overall accuracy of ioflupane[123I] imaging for the BRP dominant subgroup was still
very good, although less than for the tremor dominant
and balanced subgroups.
Discussion of findings
It has been established that SPECT imaging of presynap-
tic DaTs has utility in the premotor diagnosis of PD, as
noted in analysis of cohorts presenting with REM sleep
behavioral disorder or anosomia/hyposmia [8,9]. Further,
a large-scale audit of ioflupane [123I] imaging abnormality
in patients at initial motor presentation of PD in a UK
movement disorder service noted the majority of patients
to be at stage 2 to 3 of ioflupane [123I] imaging abnorma-
lity [10,11]. Taken together, these sets of data suggest the
possibility that ioflupane [123I] imaging might be able to
detect abnormality both at early (premotor) and later
(motor) clinical presentation, although to date there
has been no analysis of H&Y stage versus clinical uti-
lity of ioflupane [123I]. The findings in our study sup-
port this hypothetical notion of no significant effect of
H&Y stage on diagnostic accuracy of ioflupane [123I].
Whether or not diagnostic utility of ioflupane [123I]
imaging varies with stage of cognitive impairment in
CUPS has also not been analyzed to date. The findings
in our study of no effect of MMSE on accuracy of ioflu-
pane [123I] imaging suggest the technique remains accur-
ate in the context of cognitive impairment. Our analyses
did not include subgrouping of mild, moderate, or severe
dementia based on MMSE, which would have been useful,
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the technique could be of diagnostic utility even in the
presence of severe cognitive impairment [12,13].
An average age-related decline of DaT availability of
5.5% across both genders per decade has been reported
from work on normal healthy controls [14]. This reduc-
tion of DaT signal with age might affect diagnostic sensi-
tivity of the technique if abnormal ioflupane [123I] imaging
was to show subtle or minimal change between normal
and abnormal cases. Previous reports correlating ioflupane
[123I] image abnormality with first clinical presentation of
PD [10,11], however, suggest a reasonable correlation with
work from Braak and colleagues [15] suggesting that ioflu-
pane [123I] image abnormality at motor PD presentation is
in line with an estimated 60 to 80% dopaminergic cell loss
at motor presentation, and is in any case associated with
asymmetrical striatal signal loss rather than the symme-
trical loss due to ageing. In accord with the published
literature, this would be expected to yield substantial
ioflupane [123I] imaging abnormality, and the majority
of patients in this study had grade 2 to 3 abnormality
(moderate–severe) rather than grade 1 (mild). The mild
age-related symmetric reduction in DaT binding with in-
creased age would therefore probably not have a signifi-
cant effect on diagnostic performance of this test, and the
findings in our study are in keeping with this hypothesis.
There have been a number of reports on the pattern
of ioflupane [123I] image abnormality seen in the motor
subtype of PD analyzed, broadly tremor dominant versus
akinetic-rigid phenotypes [16]. These studies did not
analyze clinical utility of ioflupane [123I] imaging in mak-
ing an accurate clinical diagnosis in the two phenotypes,
although the areas of reduced dopaminergic projection
differ between the two, with visible reduction to the dor-
sal putamen in akinetic-rigid patients and in the caudate
nucleus in tremor dominant patients [16]. In general,
the differential diagnosis of a tremulous parkinsonian
presentation is more limited than that of an akinetic-
rigid presentation. The former would include tremor
dominant PD or an alternative benign tremulous condi-
tion where parkinsonian features might be noted. The
latter has been termed benign indeterminate tremor by
Deuschl and colleagues in the 1992 Movement Disorder
Society tremor classification system [17]. A further dif-
ferential to consider in these cases would be benign
tremor with parkinsonism due to an alternative caus-
ation (for example, benign tremor on an age-related
background of vascular parkinsonism) or a drug-induced
tremor–parkinsonism causation (for example, sodium val-
proate exposure) [17,18]. The differential clinical diagnosis
of akinetic-rigid phenotypes (that is, BRP in the present
analysis) is challenging and includes PD, multiple
system atrophy, progressive supranuclear palsy, and Lewy
body dementia, all of which would be expected to beassociated with loss of dopamine transporters. In con-
trast, age-related changes – possibly vascular parkin-
sonism, medication-induced parkinsonism, normal pressure
hydrocephalus, tardive parkinsonism secondary to neu-
roleptics, the Westphal variant of Huntington’s disease,
Machado-Joseph disease (SCA-3), or manganese tox-
icity – are associated with more or less preserved pre-
synaptic dopamine terminals, and with normal or less
pathological ioflupane [123I] imaging scans [19]. Not-
ably, a recent autopsy study including 16 patients with
a diagnosis of probable PD at death reported at least
seven pathologies not typically associated with dopa-
mine terminal loss (3/12, no clear pathologic process;
1/12, hippocampal sclerosis; 1/12, vascular disease; 1/12,
Alzheimer’s disease; 1/12, Alzheimer’s/vascular disease)
[20]. Conceivably, although the present study was not
controlled by postmortem data, similar clinical difficulties
may account for the lower specificity and NPV in the BRP
group in the present analysis. Given the wide range of dif-
ferential diagnosis in an akinetic-rigid parkinsonian pres-
entation, a longer duration may be needed to improve the
reference standard of 1 year in less certain cases; but 1
year should be sufficient for the tremor dominant and bal-
anced subtypes in generating an accurate long-term clin-
ical diagnosis, although this proposition has not been
formally tested. The data from this study are in keeping
with these suppositions, showing a reduced diagnostic
performance (specificity, NPV, and accuracy) in BRP
presentations versus either tremulous or balanced motor
presentation of disease. The diagnostic performance for
ioflupane [123I] imaging for the tremor dominant and bal-
anced subgroups was significantly better than for the base-
line clinical diagnosis; for the BRP dominant subgroup,
the difference did not reach statistical significance. The
specificity of baseline clinical diagnosis for BRP was infer-
ior to ioflupane [123I] imaging performance, supporting
challenges for differential work-up in this motor syn-
drome, especially in subjects with CUPS. One strategy for
improving the performance of the ioflupane [123I] imaging
in the BRP subgroup could be a quantitative evaluation of
SPECT images. Additionally, repeated ioflupane [123I] im-
aging scanning (for example, 12 or 24 months after base-
line) could be helpful in those BRP patients with initial
normal scans to determine progression of the disease.
According to our findings, the type of initial motor signs
has an observable relationship with the predictability of
performance of ioflupane [123I] imaging, with tremor dom-
inant and balanced motor scores being more highly pre-
dictive of PS than bradykinesia, rigidity, or postural
instability dominance. In our trial, the type of domin-
ant motor signs, but not the H&Y stage, MMSE score, or
age, impacted the diagnostic performance of ioflupane
[123I] imaging. Ioflupane [123I] imaging had the strongest
efficacy in tremor dominant and balanced cases of CUPS.
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This study suggests that the diagnostic performance of
ioflupane [123I] imaging in CUPS remains high at all
stages of disease, including early stage, and across both
age groups and cognitive state (MMSE). The strongest
diagnostic performance of ioflupane [123I] imaging for
clinical diagnosis of PS or non-PS was associated with
subjects with tremor dominant and balanced motor
scores rather than with BRP dominance. High diagnostic
effectiveness of ioflupane [123I] imaging in diagnosis of
CUPS was demonstrated by this study. Favorable
performance of ioflupane [123I] imaging was observed
relative to final clinical diagnosis at 1 year post scan.
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